Your browser doesn't support javascript.
Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis.
Ebinger, Joseph E; Joung, Sandy; Liu, Yunxian; Wu, Min; Weber, Brittany; Claggett, Brian; Botting, Patrick G; Sun, Nancy; Driver, Matthew; Kao, Yu Hung; Khuu, Briana; Wynter, Timothy; Nguyen, Trevor-Trung; Alotaibi, Mona; Prostko, John C; Frias, Edwin C; Stewart, James L; Goodridge, Helen S; Chen, Peter; Jordan, Stanley C; Jain, Mohit; Sharma, Sonia; Fert-Bober, Justyna; Van Eyk, Jennifer E; Minissian, Margo B; Arditi, Moshe; Melmed, Gil Y; Braun, Jonathan G; McGovern, Dermot P B; Cheng, Susan; Sobhani, Kimia.
  • Ebinger JE; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Joung S; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Liu Y; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Wu M; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Weber B; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Claggett B; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Botting PG; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Sun N; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Driver M; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Kao YH; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Khuu B; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Wynter T; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Nguyen TT; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Alotaibi M; Division of Pulmonary and Critical Care Medicine, University of California San Diego, San Diego, California, USA.
  • Prostko JC; Applied Research and Technology, Abbott Laboratories, Abbott Park, Illinois, USA.
  • Frias EC; Applied Research and Technology, Abbott Laboratories, Abbott Park, Illinois, USA.
  • Stewart JL; Applied Research and Technology, Abbott Laboratories, Abbott Park, Illinois, USA.
  • Goodridge HS; Department of Biomedical Sciences, Research Division of Immunology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Chen P; Department of Biomedical Sciences, Research Division of Immunology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Jordan SC; Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Jain M; Department of Medicine, School of Medicine, University of California, San Diego, San Diego, California, USA.
  • Sharma S; La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
  • Fert-Bober J; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Van Eyk JE; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Minissian MB; Advanced Clinical Biosystems Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Arditi M; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Melmed GY; Brawerman Nursing Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Braun JG; Smidt Heart Institute; Department of Pediatrics, Division of Infectious Diseases and Immunology; Infectious and Immunologic Diseases Research Center (IIDRC); Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • McGovern DPB; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Cheng S; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Sobhani K; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
BMJ Open ; 12(5): e059994, 2022 05 24.
Article in English | MEDLINE | ID: covidwho-1865181
ABSTRACT

OBJECTIVES:

We sought to understand the demographic and clinical factors associated with variations in longitudinal antibody response following completion of two-dose regiment of BNT162b2 vaccination.

DESIGN:

This study is a 10-month longitudinal cohort study of healthcare workers and serially measured anti-spike protein IgG (IgG-S) antibody levels using mixed linear models to examine their associations with participant characteristics.

SETTING:

A large, multisite academic medical centre in Southern California, USA.

PARTICIPANTS:

A total of 843 healthcare workers met inclusion criteria including completion of an initial two-dose course of BNT162b2 vaccination, complete clinical history and at least two blood samples for analysis. Patients had an average age of 45±13 years, were 70% female and 7% with prior SARS-CoV-2 infection.

RESULTS:

Vaccine-induced IgG-S levels remained in the positive range for 99.6% of individuals up to 10 months after initial two-dose vaccination. Prior SARS-CoV-2 infection was the primary correlate of sustained higher postvaccination IgG-S levels (partial R2=0.133), with a 1.74±0.11 SD higher IgG-S response (p<0.001). Female sex (beta 0.27±0.06, p<0.001), younger age (0.01±0.00, p<0.001) and absence of hypertension (0.17±0.08, p=0.003) were also associated with persistently higher IgG-S responses. Notably, prior SARS-CoV-2 infection augmented the associations of sex (-0.42 for male sex, p=0.08) and modified the associations of hypertension (1.17, p=0.001), such that infection-naïve individuals with hypertension had persistently lower IgG-S levels whereas prior infected individuals with hypertension exhibited higher IgG-S levels that remained augmented over time.

CONCLUSIONS:

While the IgG-S antibody response remains in the positive range for up to 10 months following initial mRNA vaccination in most adults, determinants of sustained higher antibody levels include prior SARS-CoV-2 infection, female sex, younger age and absence of hypertension. Certain determinants of the longitudinal antibody response appear significantly modified by prior infection status. These findings offer insights regarding factors that may influence the 'hybrid' immunity conferred by natural infection combined with vaccination.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-059994

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-059994